Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Washer 

Neurocrine Bioscience diskutieren

Neurocrine Bioscience

WKN: 900964 / Symbol: NBIX / Name: Neurocrine / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /

127,05 €
-0,51 %

Einschätzung Buy
Rendite (%) 2,46 %
Kursziel 136,69
Veränderung
Endet am 23.02.25

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target lowered by analysts at JPMorgan Chase & Co. from $154.00 to $148.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat

Einschätzung Buy
Rendite (%) -1,01 %
Kursziel 183,92
Veränderung
Endet am 18.03.25

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Oppenheimer Holdings Inc. from $170.00 to $200.00. They now have an "outperform" rating on the stock.
Ratings data for NBIX provided by MarketBeat

Einschätzung Buy
Rendite (%) -1,40 %
Kursziel 145,64
Veränderung
Endet am 20.03.25

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at JPMorgan Chase & Co. from $148.00 to $158.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat

Einschätzung Buy
Rendite (%) -1,93 %
Kursziel 144,01
Veränderung
Endet am 10.04.25

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $155.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat

Einschätzung Buy
Rendite (%) -5,85 %
Kursziel 140,34
Veränderung
Endet am 24.04.25

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $150.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat

Einschätzung Buy
Rendite (%) -5,85 %
Kursziel 187,12
Veränderung
Endet am 24.04.25

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $200.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat